Philips Collaborates with Janssen on Handheld Test for Neuropsychiatric Disorders
By LabMedica International staff writers Posted on 05 Apr 2015 |
Royal Philips (Amsterdam, Netherlands) has entered into a multiyear development agreement with Janssen Pharmaceutica NV (Beerse, Belgium) to develop a novel point-of-care (POC) blood test to improve the care of patients with neuropsychiatric disorders.
The collaboration unites Philips’ expertise in POC diagnostics and monitoring applications for hospital and home with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for development and manufacturing of the handheld test, which will be based on Philips’ “Minicare” system currently under development. Janssen will be responsible for the clinical validation studies, as well as commercialization of the final product. Minicare is part of Philips’ Handheld Diagnostics business (Eindhoven, Netherlands), which will be expanding its production capacity in light of the new partnership.
The blood test will be based on Minicare I-20 for immunoassays, which consists of a handheld analyzer, dedicated software, and a single-use, disposable cartridge containing the application-specific test. Based on Philips’ proprietary biosensor technology, Minicare I -20 is being developed to detect multiple target molecules at low concentrations within a single blood sample and to provide the results on the analyzer display within minutes.
“Our technology can play an important role in the management of chronic diseases,” said Frans van Houten, CEO, Royal Philips, “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.”
“Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software can be tailored to a wide range of other pharmaceuticals,” added Mr. Van Houten.
Related Links:
Royal Philips
Janssen Pharmaceutica
The collaboration unites Philips’ expertise in POC diagnostics and monitoring applications for hospital and home with Janssen’s strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for development and manufacturing of the handheld test, which will be based on Philips’ “Minicare” system currently under development. Janssen will be responsible for the clinical validation studies, as well as commercialization of the final product. Minicare is part of Philips’ Handheld Diagnostics business (Eindhoven, Netherlands), which will be expanding its production capacity in light of the new partnership.
The blood test will be based on Minicare I-20 for immunoassays, which consists of a handheld analyzer, dedicated software, and a single-use, disposable cartridge containing the application-specific test. Based on Philips’ proprietary biosensor technology, Minicare I -20 is being developed to detect multiple target molecules at low concentrations within a single blood sample and to provide the results on the analyzer display within minutes.
“Our technology can play an important role in the management of chronic diseases,” said Frans van Houten, CEO, Royal Philips, “Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform.”
“Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software can be tailored to a wide range of other pharmaceuticals,” added Mr. Van Houten.
Related Links:
Royal Philips
Janssen Pharmaceutica
Latest Industry News
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million